Veeva Systems: Near-Term Challenges But Good Prospects Long Term
Positive results amid near-term challenges. Long-term dominance in a growing industry and continued growth from inorganic and organic strategies. Fortress balance sheet.
Has the U.S. Healthtech Industry valuation changed over the past few years?
|Sat, 28 May 2022||US$116.6b||US$23.2b||-US$7,359,237,621.00||49x|
|Mon, 25 Apr 2022||US$131.2b||US$23.8b||-US$823,593,303.00||65.7x|
|Wed, 23 Mar 2022||US$141.8b||US$23.9b||-US$869,737,328.00||83x|
|Fri, 18 Feb 2022||US$152.4b||US$23.9b||-US$1,703,521,715.00||90.3x|
|Sun, 16 Jan 2022||US$156.4b||US$23.7b||-US$1,729,195,532.00||92.6x|
|Tue, 14 Dec 2021||US$168.9b||US$23.1b||-US$1,291,880,240.00||97.6x|
|Thu, 11 Nov 2021||US$203.0b||US$22.9b||-US$1,341,755,766.00||113x|
|Sat, 09 Oct 2021||US$188.8b||US$22.1b||-US$1,254,921,150.00||105.8x|
|Mon, 06 Sep 2021||US$197.2b||US$21.9b||-US$1,313,886,449.04||92.8x|
|Wed, 04 Aug 2021||US$188.7b||US$21.9b||-US$1,229,889,348.31||94.4x|
|Sat, 08 May 2021||US$170.8b||US$20.3b||-US$1,351,563,571.31||93.6x|
|Tue, 09 Feb 2021||US$188.6b||US$19.1b||-US$2,269,608,711.31||81.3x|
|Mon, 02 Nov 2020||US$150.5b||US$17.5b||-US$1,422,222,372.31||92.6x|
|Thu, 06 Aug 2020||US$110.7b||US$14.9b||-US$1,221,765,849.31||42.7x|
|Sun, 10 May 2020||US$86.3b||US$14.2b||-US$1,262,876,112.31||44.3x|
|Sat, 01 Feb 2020||US$73.5b||US$13.6b||-US$316,037,126.31||55.6x|
|Tue, 05 Nov 2019||US$67.9b||US$13.4b||-US$263,823,532.31||48.5x|
|Fri, 09 Aug 2019||US$74.5b||US$13.1b||-US$85,430,019.31||50x|
How does U.S. Healthtech compare with similar industries?
Which companies have driven the market over the last 7 days?
Healthcare technology tickers have been one of the hardest-hit industries on the market and MultiPlan Corporation appears to be trading at a 70%+ discount based on certain valuation models. MultiPlan processed roughly $31.7B in claim charges during the quarter and identified ~$5.6B in potential cost savings. As a result, the company’s Q1 revenues came in at $298M. The company is maintaining their 2022 guidance with revenues expected to come in between $1.16B and $1.2B. In addition, the company expects cash flow from operations to be in the range of $380M-$420M. I see MPLN as a great opportunity to add a high-quality HCIT ticker to the Bio Boom portfolio.
Inspire Medical Systems
Medical equipment producers suffered demand constrictions as Covid-19 hospital capacity and personnel were conscripted to handle the pandemic. INSP stock recuperated from $50 to $250 in a year. Today’s MM-hedging induced price range forecast sees a 23%+ gain from shared current market price depression to return to the $185 base of its prior-year range. Tests of the prior outcomes of as seen-today forecasts for over 3,000 equity alternatives, for how big, how sure, how soon net benefits may recover appear more likely than average. Alternatives presented include those identified by Yahoo Finance as being “similar to” the subject, or stocks which “people also watch” as well as the subject, plus those present as holdings in the industry-focus ETF.
Teladoc has dropped more than 60% since the beginning of April, destroying billions of shareholder wealth. Business growth remained intact, but compressing margins and the need to spend massively on marketing are noteworthy issues. Teladoc is not trading at a high sales multiple, but until the business model and profitability are proven, TDOC remains a risky bet.